Canada authorizes Mo-99 production at Darlington station
The Canadian Nuclear Safety Commission (CNSC) has amended Ontario Power Generation’s (OPG) operating license for its Darlington nuclear power station near Clarington, Ontario, allowing the company to produce the medical radioisotope molybdenum-99 using Darlington’s Unit 2 CANDU reactor. OPG subsidiary Laurentis Energy Partners, in conjunction with BWXT Medical, is leading the program to produce Mo-99 at Darlington.